Product Description
UM171 patients benefit from rapid T cell reconstitution, which likely contributes to the absence of moderate/severe cGVHD, infection-related mortality, and late TRM observed in this cohort. Recently, results of a phase I/II trial revealed that single UM171-expanded CB transplant allowed the use of smaller CB units without compromising engraftment (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33022376/)
Mechanisms of Action: Cell Therapy,CD34
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ExCellThera
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Netherlands, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Allogeneic Stem Cell Transplant|Graft vs Host Disease|Hematopoietic Stem Cell Transplant|Multiple Myeloma|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-002458-26 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome|Allogeneic Stem Cell Transplant |
2027-08-09 |
|
| ECT-001-CB.007 | P2 |
Recruiting |
Hematopoietic Stem Cell Transplant|Graft vs Host Disease |
2026-06-01 |
24% |
| ECT-001-CB.004 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome|Preleukemia |
2026-02-01 |
24% |
| ECT-001-CB.002 | P2 |
Active, not recruiting |
Preleukemia|Myelodysplastic Syndrome |
2024-10-01 |